The prognostic impact of Wilms tumor-1 polymorphism (rs16754) and human myeloid inhibitory C-type lectin-like receptor expression in cytogenetically normal-acute myeloid leukemia
Open Access
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Egyptian Journal of Medical Human Genetics
- Vol. 22 (1), 1-12
- https://doi.org/10.1186/s43042-021-00183-8
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHaematologica, 2011
- WT1 Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Monoclonal antibody therapy directed against human acute myeloid leukemia stem cellsOncogene, 2010
- Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapseAPMIS, 2010
- The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemiaHematological Oncology, 2009
- Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2008
- The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesisExpert Reviews in Molecular Medicine, 2007
- A tumor suppressor and oncogene: the WT1 storyLeukemia, 2007
- Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implicationsLeukemia, 2006
- C-Type Lectin-Like Molecule-1Cancer Research, 2004